Astrazeneca Pharma India Limited · NSE:ASTRAZEN
Astrazeneca Pharma India — Shareholder Meeting (August 2026)
30 slides from Astrazeneca Pharma India's shareholder meeting presentation, Aug 10, 2026
Slide 1: AstraZeneca Pharma India Limited 47th Annual General Meeting
AstraZeneca Pharma India Limited 47th Annual General Meeting Praveen Rao Akkinepally, Managing Director & Country President AstraZeneca Pharma India Ltd. 10th August 2026
Slide 2: Disclaimer
Disclaimer This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present
Slide 3: AZPIL Board of Directors
AZPIL Board of Directors Board of Directors Shilpa Divekar Nirula Revathy Ashok Monica Widhani Hooi-Bien Chuah Praveen Rao Akkinepally Bhavana Agrawal Chairperson & Non-Executive Non-Executive Non-Executive Director Managing Director & Chief Financial Officer & Non-Executive Independent Director Indep
Slide 4: Agenda
Agenda • Global Update • India Update • Oncology Agenda • Biopharmaceuticals • Rare Disease • Sustainability • Great Place to Work
Slide 5: Global & India Update
Global & India Update Praveen Rao Akkinepally, Managing Director & Country President AstraZeneca Pharma India Limited
Slide 6: Our bold aspiration: pioneers in science, lead in disease areas, harness AI
Our bold aspiration is to be pioneers in science, lead in our disease areas, and harness the power of AI to transform patient outcomes. By 2030, we will deliver 20 new medicines, lead in sustainable healthcare, and be an $80bn company.
Slide 7: Growth powered by diverse global presence and sources of business
Growth powered by diverse global presence and sources of business Due to rounding, the sum of the percentages may not agree to totals. 1. All growth rates at CER.
Slide 8: Delivering today, tomorrow and the day after
Delivering today, tomorrow and the day after Beyond 2030 ADCs and radioconjugates Cell therapy and T-cell engagers $80bn Launching key NMEs Gene therapy AZD0120 saruparib Next-generation IO bispecifics Illustrative only, not to scale camizestrant volrustomig rilvegostomig AZN ADCs Weight management
Slide 9: Strategically investing to deliver growth beyond 2030
Strategically investing to deliver growth beyond 2030 Significant progress across our transformative technologies in FY 2025 As of 10 February 2026.
Slide 10: AI30: Our pledge to patients and a collective commitment
AI30: Our pledge to patients and a collective commitment to shift our enterprise into a higher gear 30%+ 30%+ 30%+ Smarter More precise Faster More human freeing our people to care, create and lead
Slide 11: In India, our purpose is helping more patients live better, healthier lives
In India, our purpose is focused around helping more patients live better, healthier lives
Slide 12: Country macro economic environment
Country macro economic environment GDP Pharma Market Expansion GDP : $4.15 Trillion (6th Largest-latest IMF data) Projected to double to ~$130B by 2030 GDP growth : ~6.5 (2026 IMF); 10-12% CAGR; Rising incidences across Therapeutic Areas Healthcare a State Subject, India spends ~3.3% of GDP on HC in
Slide 13: AZPIL delivers robust double-digit growth
AZPIL delivers robust double-digit growth Strong commercial performance and financial % Sales by therapy area execution in FY 2025-26 Total Revenue (INR in Mn) +31% 23041 17569 FY 2024-25 FY 2025-26
Slide 14: AstraZeneca is amongst the fastest growing companies in Indian Pharmaceutical Market
AstraZeneca is amongst the fastest growing companies in Indian Pharmaceutical Market Ranks 7th amongst MNCs in IPM2 Oncology business ranks 2nd in IPM1 #4 NPM >115 patients >120 patients in 2025 #3 IN #5 IN #6 IN #1 OAP #1 Biologic In IN in 2025 Oncology Oncology Oncology in IN In IN Source: 1. IPSO
Slide 15: Bringing our innovative medicines faster to India
AP1 Bringing our innovative medicines faster to India Additional Indications Himalaya Duo E Mono Mono Flaura 2 DB-06 Laura EGPA DUO-E Niagara DPT02 Matterhorn Launched
Slide 16: Unlocking access through impactful partnerships
Unlocking access through impactful partnerships MoU for AI based cancer MoU for AI based cancer WEF dialogue on cancer Project Pandora in Goa APPEAL-Advocacy for screening in Tamil Nadu screening in Telangana continuum care in AP for AI enabled screening dedicated funding for cancer
Slide 17: Advocating for expanding access to next-gen medicines
Advocating for expanding access to next-gen medicines Inclusion of our recommendations in the Inclusion of cancer and RD drugs in the lung cancer treatment and palliation BCD exemption list tabled by GOI during guidelines launched by MoHFW Budget session 2025-26
Slide 18: Integrating AI every day to deliver AI30 strategy
Integrating AI every day to deliver AI30 strategy AI Accelerator program Introducing myAZ on MS Smarter. Faster. Better: AZ IN first market to use Season 2 launched teams –a daily companion ChatGPT ‘smart’ companion for HCP calls
Slide 19: Recognised for advancing our purpose and vision
Recognised for advancing our purpose and vision ET-Pharma Company of OPPI- Medical & Marketing the Year 2025’ Award Excellence Award Only pharma company in the top 20 AstraZeneca India is now ‘Top Employer’
Slide 20: Therapy Areas we are present in
Therapy Areas we are present in: Oncology Biopharmaceuticals Rare Disease
Slide 21: Oncology continues robust growth supported by innovative science & access
Value in INR mn Oncology continues robust growth supported by innovative science & access IPSOS GR% (MAT DEC 25 vs MAT DEC 24) OBU TA PERFORMANCE (Mn) KEY BRAND PERFORMANCE GR% 5,736 34% 16,110 40% 44% 4,971 68% 11,171 22% 4,045 48% 531 4% AZ Market FY 2024-25 FY 2025-26 AZ Rank MAT Dec’25 2 (1) IPS
Slide 22: Transforming Care through collaborations
Transforming Care through collaborations ‘Shuruaat’ campaign to highlight patient LuNGS Alliance to enhance lung voices around cancer management and Preceptorship Programme & AAZPIRE cancer NGS testing to enable precision early detection; reached >15.7 million Supported clinical education, research
Slide 23: Biopharmaceuticals continues growth with focus on specialist portfolio and new product pipeline
AP1 Value in INR mn Biopharmaceuticals continues growth with focus on specialist portfolio and new product pipeline BBU TA Performance (Mn) KEY BRAND PERFORMANCE GR 7% 5,234 4,881 FY 2024-25 FY 2025-26
Slide 24: Transforming chronic care through Patient Centricity
Transforming chronic care through Patient Centricity K+ Connect, cross-specialty cardio Partnered with ISN and the HFA to co- India Coronary Conquest 2026 nephrology dialogues designed to create India-specific HK Harmony specialist engagement and encourage peer-to-peer discussion Consensus, an algor
Slide 25: Rare Disease strengthening foundation and shaping the ecosystem
Value in INR mn Rare Disease strengthening foundation and shaping the ecosystem RD TA Performance (Mn) 7x 215 32 FY 2024-25 FY 2025-26
Slide 26: Our refreshed Sustainability Strategy
Our refreshed Sustainability Strategy Recognising the interconnection between business growth and addressing the major health challenges of our time, our Sustainability strategy focuses on how we make a positive impact for people, society and the planet and how we do business. 26
Slide 27: CSR program impact last FY 2025-26
CSR program impact last FY 2025-26 Water and Khandala lake Desertguard row Young Health soil conservation rejuvenation plantation project Program • A watershed management • Helped address pertinent • Supporting "functional • Reducing NCD risk factors by project in Satara, water crisis in Maharashtra
Slide 28: Our GPTW strategy is aligned to People Development
Our GPTW strategy is aligned to People Development INTERNAL PULSE SURVEY 97% 94% 91% 88% India market employees Employees understand AZ’s Employees feel Inspired to do Employees feel managers are participated in the survey future direction and key their best work at AZ committed to D&I priorities PE
Slide 29: Our Values and Behaviours are our strongest anchor
Our Values and Behaviours are our strongest anchor We Follow We Put We Play We Do the We are the Science Patients First to Win Right Thing Entrepreneurial
Slide 30: Thank you
Thank you for your contribution and support to our growth story.
AstraZeneca Pharma India — Shareholder Meeting (August 2026) on 6ix